|
|
|
 Haematology Probes |
|
Cytocell offers a range of haematology probes specific for a number of haematological malignancies which are available in the Aquarius® liquid format.
These probes are directly labelled, ready to use in hybridisation buffer and are supplied in an economical 10 test format. The protocol is rapid and simple and has been developed to allow co-denaturation of the FISH probe and target DNA simultaneously.
The probe mixtures are designed for fluorescence in situ hybridisation of interphase cells and metaphase chromosomes from cultured peripheral blood cells or cultured bone marrow samples.
Features : |
> Aquarius liquid probe format
> Ready to use: pre-mixed in hybridisation solution
> Simple and clean: co-denaturation protocol
> 10 assay kit format which includes DAPI counterstain and full instructions for use
|
|
Cytocell offers a range of haematology probes specific for a number of haematological malignancies
which are available in the Aquarius® liquid format ! |
> Ready to use: pre-mixed in hybridisation solution
> Simple and clear : co-denaturation protocol
> 10 TESTS kit format which includes DAPI counterstain and full instructions for use
> Complement to Multiprobes LLC, LAL and LAM Panels
|
 |
 |
BCR/ABL double fusion Probe Haemato-oncology laboratory - CHU Hautepierre Strasbourg |
|
| Probe Description |
Locus |
Type of probe |
Control locus |
Nbr of
Tests |
Reference |
| ATM Probe |
11q22 |
Deletion |
D11Z1
|
10 |
LPH011 |
| P53 Probe |
17p13 |
Deletion |
D17Z1 |
10 |
LPH017 |
| MYB Probe |
6q23 |
Deletion |
D6Z1 |
10 |
LPH016 |
| MYC Probe |
8q24 |
Breakapart |
N/A |
10 |
LPH010 |
P16 Probe
|
9p21
|
Deletion
|
D9Z3
|
10 |
LPH009 |
| Del(20q) |
20q12/20q13.2 |
Deletion |
D20Z1 |
10 |
LPH020 |
| MLL Probe |
11q23 |
Breakapart |
N/A |
10 |
LPH013 |
| IGH Probe |
14q32 |
Breakapart |
N/A |
10 |
LPH014 |
| TEL/AML Probe |
12p13/21q22 |
Translocation |
N/A |
10 |
LPH012 |
13q14.3 Deletion Probe
|
13q14.3 |
Deletion |
13qter |
10 |
LPH006 |
| CHIC2 Probe |
4q11-12 |
Deletion |
4qter |
10 |
LPH015 |
| MYH11 (16p13.1) |
16p13.1 |
Breakapart |
N/A |
10 |
LPH003 |
| PML/RARα Single Fusion |
15q22/17q21 |
Translocation |
N/A |
10 |
LPH004 |
BCR/ABL Dual Fusion
|
9q34/22q11 |
Translocation |
N/A |
10 |
LPH007 |
| E2A Probe |
19p13 |
Breakapart |
N/A |
10 |
LPH019 |
| IGH/CCND1 Probe |
14q32/11q13 |
Translocation |
N/A |
10 |
LPH021 |
| IGH/BCL2 Probe |
14q32/18q21 |
Translocation |
N/A |
10 |
LPH018 |
*CBFB/MYH11
|
16q22/16p13
|
Translocation
|
N/A |
10 |
LPH022 |
| *PML/RARα Dual Fusion |
15q22/17q21 |
Translocation |
N/A |
10 |
LPH023 |
*Under development |
| MYH11 (16p13.1) breakpoint probe |
Proximal Probe: Green Fluorophore Distal Probe: Red Fluorophore
10 tests – Reference LPH003
Download the protocol |
 |
Inv(16)(p13q22) and t(16;16)(p13;q22), often missed by conventional cytogenetics in a third of patients, are found in 10% of patients with de novo acute myeloid leukaemia (AML) and are most commonly associated with M4 with abnormal eosinophilia. In these rearrangements the core binding factor beta gene on 16q22 is fused to the smooth muscle heavy chain gene (MYH11) on 16p13 giving a transcribed fusion gene. The rearrangements are recognised as positive prognostic factors in de novo adult AML.
The MYH11 Probe mixture contains sequences proximal and distal to the 16p breakpoint which are dual labelled, in green and red respectively. |
 |
|
| PML/RARA translocation probe |
PML (15q22): Red Fluorophore RARα (17q21): Green Fluorophore
10 tests – Reference LPH004
Download the protocol |
 |
The translocation t(15;17)(q22;q21) is the diagnostic hallmark of Acute Promyelocytic Leukaemia and leads to the formation of PML-RARα and RARα-PML fusion genes. The PML-RARα fusion protein is typically transcribed from the derived chromosome 15, but RARα-PML is not expressed in 25% of patients. Establishing the existence of the t(15;17) or the PML-RARα rearrangement, is fundamental for optimal treatment of patients. Interstitial insertion events have also been detected when chromosomes 15 and 17 have appeared normal by conventional cytogenetics. The PML/RARα Translocation Probe mixture is directly labelled and contains the 5' region of the PML gene including exons 1 and 2 (red) and sequences from exon 2 to 9 from RARa (green). This type of probe may be used to identify the PML/RARα fusion gene. |
 |
|
| 13q14.3 deletion probe |
D13S319-D13S25: Red Fluorophore 13q Subtelomere Specific probe (clone 163C9): Green Fluorophore
10 tests – Reference LPH006
Download the protocol |
 |
Deletions in 13q14 are common genetic alterations in B-cell neoplasm, from Acute Lymphoblastic Leukaemia to Multiple Myeloma and non-Hodgkin's Lymphoma. Deletions are observed in 30% of karyotypically normal Multiple Myeloma patients and in over 20% of B-cell Chronic Lymphocytic Leukaemia (CLL) patients. A further 20% have microscopic deletions and 10% exhibit homozygous loss. The large (~2 Mb) deletions are telomeric to the Retinoblastoma gene, flanked by the markers D13S273 and D13S25. CLL patients with a 13q14.3 deletion have a better prognosis than patients with trisomy 12.
The 13q14.3 deletion probe covers the region 100 Kb centromeric to D13S319 through to the marker D13S25. The probe mix is directly labelled, with 13q14.3 in red and the 13qter control probe in green.
|
 |
|
| Related Products |
The Chromoprobe Multiprobe CLL Panel has been designed to detect multiple rearrangements that occur in Chronic lymphocytic leukaemia (CLL) - the most common of the B-cell lineage lymphoproliferative disorders. The panel can be used to rapidly determine genotype in leukaemia patients and aid in prognosis and treatment. |
The Chromoprobe Multiprobe ALL Panel has been designed to detect multiple rearrangements that occur primarily in B-cell lineage ALL in addition to several T-lineage markers. The panel can be used to rapidly determine genotype in leukaemia patients and aid in prognosis and treatment. |
|
|
|
